CLINICAL TRIALS – PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart ...

Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) ...

I'm Toko, a public relations committee member for ODNJ.Last time, I wrote about the day I discovered the "gateway to research ...

It has been over a month since I realized it, but from September 11th to 13th, 2026, I participated in the Japan Society of ...

Submit a poster to the 2026 Q2B x Chicago Quantum Summit by November 10 for a chance to win awards and receive a ...

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a ...

Posters detail new dual-mechanism muscle capsids, a cross-species capsid targeting alkaline phosphatase for CNS and muscle ...

Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment ...

Delighted to Share That Our Abstract Accepted for Poster Presentation at ESMO 2026 / anticancer agent, anticancer treatment, ...

Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN ...